September 10, 2025CureusOpen Access

Effects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Prospective observational study reveals dapagliflozin improves glycemic control in obese patients, indicating safety and efficacy.

Dapagliflozin significantly reduced HbA1c levels from 8.1 to 7.3 after six months of treatment, demonstrating its effectiveness.
Adverse events in 16% of patients included fatigue and hypoglycemia, highlighting potential risks associated with the treatment.
The study involved 1,500 obese patients with type 2 diabetes, reflecting real-world effectiveness of dapagliflozin therapy.
Improvements in metabolic parameters suggest dapagliflozin’s clinical utility, supporting its adoption in daily medical practice.

Akhond et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 10, 2025CureusOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Prospective observational study reveals dapagliflozin improves glycemic control in obese patients, indicating safety and efficacy.

Dapagliflozin significantly reduced HbA1c levels from 8.1 to 7.3 after six months of treatment, demonstrating its effectiveness.
Adverse events in 16% of patients included fatigue and hypoglycemia, highlighting potential risks associated with the treatment.
The study involved 1,500 obese patients with type 2 diabetes, reflecting real-world effectiveness of dapagliflozin therapy.
Improvements in metabolic parameters suggest dapagliflozin’s clinical utility, supporting its adoption in daily medical practice.

Akhond et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark